ASBP News & Events

spire Biopharma Holdings announced that its wholly owned subsidiary Buzz Bomb Caffeine Company has named ChicExecs as its public relations agency of record. ChicExecs will spearhead BUZZ BOMB's communications strategy. The focus includes media relations, high-impact events, strategic partnerships, and PR-led campaign planning.

Aspire Biopharma files to sell 159.1M shares of common stock for holders

Aspire Biopharma Holdings announced the filing of a provisional patent application with the U.S. Patent and Trademark Office for its proprietary sublingual powder formulation of Meclizine. The application, titled "A Sublingual Powder Formulation of Meclizine and Methods of Use Thereof," represents a significant leap in antiemetic therapy. By introducing the first-ever sublingual powder delivery system for Meclizine, Aspire aims to eliminate the traditional "waiting period" associated with oral tablets, providing near-instant relief for nausea, vomiting, and vertigo.

Aspire Biopharma announced the appointment of Phillip Balatsos to its Board of Directors, effective February 6. The appointment follows the planned departures of Suren Ajjarapu and Donald Fell, from the board. Phillip Balatsos is a senior financial markets executive and board director with over 25 years of experience across foreign exchange, emerging markets, institutional sales and trading, and public company governance. He has held leadership roles at global financial institutions including Barclays Capital, Credit Suisse, and XP Investments, and currently operates within an independent trading platform at Oscar Gruss & Son. Phillip Balatsos will serve on the Audit and Compensation Committees.